Nugenyx Preparation Guide

This guide is designed to support proper storage and handling of Nugenyx products, including both vials and injection pens aswell ascommonly discussed anecdotal dosages. Following these guidelines helps maintain product quality, stability, and integrity from delivery through ongoing use.

Vial
Pen

Vial Instructions

These steps are designed to guide you through preparing, using, and storing vial based products such as NuCell NAD+ with clarity and care.

Take your time, work in a clean space, and follow each step gently. Precision and calm handling help ensure the vial remains clear, stable, and ready for use.

STEP 1. Prepare Your Space

Artistry in action

  1. Before you begin:
  2. Wash your hands thoroughly
  3. Choose a clean, well-lit surface
  4. Lay out your vial, Bac Water, syringe, and alcohol swab

STEP 2. Reconstitute the Vial

Uncompromising standards

  1. Remove the caps from the peptide vial and the water vial
  2. Clean both rubber stoppers with an alcohol swab
  3. Draw the required amount of bacteriostatic water into a sterile syringe

STEP 3. Dissolve Gently

Made to last

  1. Insert the needle into the vial
  2. Slowly inject the water down the inside wall of the vial
  3. Gently swirl the vial until the solution becomes clear - Do not shake
  4. Once clear, the peptide is fully reconstituted and ready.

STEP 4. Prepare Your Dose

Quality you can feel

  1. Draw your intended dose into a sterile syringe
  2. Gently remove any air bubbles by tapping the syringe with needle end pointing up so any air rises to the top
  3. If there is an air bubble gently press the blunger until a small
  4. amount of liquid comes out.

Your syringe is now prepared.

STEP 5. Injection

  1. Choose an appropriate subcutaneous injection site, such as the lower abdomen or thigh
  2. Clean the injection site with an alcohol swab and allow it to dry
  3. Gently pinch the skin to create a small fold
  4. Insert the needle
  5. Slowly depress the plunger until the full dose is delivered
  6. Withdraw the needle smoothly and apply light pressure with a clean swab if needed
  7. Dispose of the syringe safely in an appropriate sharps container

Quality you can feel

Storage After Use

Quality you can feel

Store reconstituted vials in a refrigerator (2–8°C)

  • Protect from light
  • Do not freeze
  • The solution should remain clear

Pen Instructions

These steps are designed to guide you through preparing, using, and storing injection pen products such as NuCell NAD+ with clarity and care.

Take your time, work in a clean space, and follow each step gently. Calm, precise handling helps ensure the pen remains stable, accurate, and ready for consistent use.

STEP 1. Prepare Your Space

Artistry in action

  1. Wash your hands thoroughly.
  2. Choose a clean, well-lit surface.
  3. Ensure your pen, a new needle tip, and an alcohol prep pad are ready.

STEP 2. Attach a New Needle

Uncompromising standards

  1. Remove the protective seal from a new pen needle.
  2. Screw or click the needle firmly onto the pen.
  3. Remove the outer needle cap and set it aside.
  4. Remove and discard the inner needle cap.

STEP 3. Prime the Pen

Made to last

Priming ensures the pen is free of air and ready for accurate dosing.

  1. Set the pen to a small priming dose (as indicated by the pen instructions).
  2. Hold the pen upright with the needle pointing upward.
  3. Gently tap the pen to move any air bubbles to the top.
  4. Press the injection button until a small drop of liquid appears at the needle tip.

Your pen is now primed and ready.

STEP 4. Set Your Dose

Quality you can feel

  1. Turn the dose selector to your intended dose.
  2. Confirm the correct number is clearly visible in the dose window.
  3. Do not adjust the dose once the needle is inserted.

STEP 5. Injection

Made to last

  1. Choose an appropriate subcutaneous injection site, such as the abdomen or thigh.
  2. Clean the area with an alcohol swab and allow it to dry.
  3. Gently pinch the skin to create a fold.
  4. Insert the needle at a shallow angle.
  5. Press the injection button fully and hold for several seconds to ensure the full dose is delivered.
  6. Remove the needle smoothly.

STEP 6. Remove and Dispose of the Needle

Made to last

  1. Carefully place the outer needle cap back onto the needle.
  2. Unscrew the needle from the pen.
  3. Dispose of the needle safely in an appropriate sharps container.
  4. Never store the pen with a needle attached.

STEP 7. Storage After Use

Made to last

  1. Store the pen in a refrigerator (2–8°C)
  2. Protect from light
  3. Do not freeze
  4. Keep the pen cap on when not in use

Confused About Dosage?

Find commonly discussed protocols in research to best fit your exploration below

Usage Reference Guide

Nugenyx encourages informed, responsible exploration, supported by independent research and engagement with credible scientific and clinical sources.

The ranges below reflect commonly observed practice patterns across clinics, studies, and experienced users. They are provided as a general reference to support understanding and informed decision-making.

They are not medical advice, treatment guidance, or personalised recommendations.

Individual response can vary, and professional guidance should always be sought where appropriate.

Gentle range
0.2 – 0.3 mg daily | 8–16 weeks

Common range
0.3 – 0.6 mg daily | 6–10 weeks

Intensive range (short term)
0.6 – 1.0 mg daily | 3–6 weeks

How This Is Commonly Used in Practice
Often used in moderate daily amounts over several weeks, with higher ranges kept short.

Tolerance & Individual Response

• Mild injection-site irritation in some users
• Occasional headache or fatigue
• Digestive discomfort in sensitive individuals

Gentle range
2 mg weekly | 12–20 weeks

Common range
3 – 5 mg weekly | 6–12 weeks

Intensive range (short term)
6 – 8 mg weekly | 4–6 weeks

How This Is Commonly Used in Practice
Typically used weekly in moderate amounts, with higher ranges reserved for short windows.

Tolerance & Individual Response

• Temporary fatigue in some users
• Mild joint or muscle soreness
• Occasional flushing

Gentle range
0.5 – 1.0 mg daily | 12–24 weeks

Common range
1.0 – 1.5 mg daily | 8–12 weeks

Intensive range (short term)
1.5 – 2.5 mg daily | 3–6 weeks

How This Is Commonly Used in Practice
Most people sit around ~1 mg daily for longer blocks. Some explore slightly higher ranges for shorter periods.

Tolerance & Individual Response
Some individuals may notice mild, temporary effects, while many experience no noticeable issues.

• Occasional redness or warmth at the injection site
• Headache or “wired” feeling in some users
• Sensitivity in individuals with lower copper tolerance
• Temporary skin reactions in sensitive users

Each NuGlow pen contains:

GHK-Cu 50 mg | BPC-157 10 mg | TB-500 10 mg in 2.0 mL (200 IU)

Approximate delivery per 1 IU (click):
GHK ~0.25 mg | BPC ~0.05 mg | TB ~0.05 mg

Gentle range
4 IU daily | 12–24 weeks

Delivers approx:
GHK ~1.0 mg | BPC ~0.2 mg | TB ~0.2 mg

Common range
6 – 8 IU daily | 8–12 weeks

Delivers approx:
GHK ~1.5–2.0 mg | BPC ~0.3–0.4 mg | TB ~0.3–0.4 mg

Intensive range (short term)
10 – 12 IU daily | 3–6 weeks

Delivers approx:
GHK ~2.5–3.0 mg | BPC ~0.5–0.6 mg | TB ~0.5–0.6 mg

How This Is Commonly Used in Practice

Most users begin in the gentle range to assess individual response, then move into the common range for a focused regeneration window. Higher ranges are typically reserved for short-term use rather than continuous exposure.

Tolerance & Individual Response

Some individuals may notice mild, temporary effects, while many experience no noticeable issues.

• Occasional redness or warmth at the injection site
• Headache or flushing in some users
• Sensitivity to copper signalling in some individuals
• Mild fatigue during higher exposure

Retatrutide research commonly follows progressive titration models, rather than fixed-dose designs. Exposure is often increased in stages based on tolerance and response.

Individual variability is significant.

Lower-range titration (conservative escalation)

0.5 – 1.0 mg weekly | 4–6 weeks
→ 1.0 – 2.0 mg weekly | 6–8 weeks
→ 2.0 – 3.0 mg weekly | 6–8 weeks

Often referenced in sensitivity, tolerance, and early metabolic studies.

Mid-range titration (moderate escalation)

1.0 mg weekly | 4 weeks
→ 2.0 mg weekly | 4–6 weeks
→ 3.0 – 4.0 mg weekly | 8–12 weeks

Commonly discussed in body-composition and insulin-sensitivity research.

Upper-range titration (advanced / higher-exposure models)

1.0 mg weekly | 2–4 weeks
→ 2.5 mg weekly | 2–4 weeks
→ 4.0 – 6.0 mg weekly | 4–8 weeks
→ up to 8.0 mg weekly | 4–6 weeks

Appears in intensive obesity and metabolic-disorder research contexts.

Important Note
Retatrutide research frequently adjusts titration speed and ceiling based on individual response, tolerance, and study design. Fixed dosing models are uncommon.

NAD⁺ protocols commonly follow a loading and maintenance structure designed to support cellular energy and mitochondrial function.

Loading range (initiation / restoration phase)

50 – 100 mg daily | 5–7 days

Commonly used to elevate baseline NAD⁺ levels and support early cellular repletion.

Some higher-intensity models reference:

100 – 150 mg daily | 3–5 days

Typically in short-duration fatigue, recovery, or neuro-focused contexts.

Maintenance range (ongoing support)

Common maintenance
50 mg EOD | 8–16 weeks

Higher exposure (short term)
75–100 mg EOD | 4–8 weeks

Tolerance & Individual Response

• Warmth or flushing
• Mild nausea
• Headache
• Fatigue in some users

Delivery Context

These ranges reflect commonly discussed subcutaneous NAD⁺ models.

Outcomes and exposure profiles differ substantially from IV infusion or oral precursor studies.

Gentle range
0.1 mg daily | 12–20 weeks

Common range
0.2 – 0.3 mg daily | 8–12 weeks

Intensive range (short term)
0.4 – 0.5 mg daily | 4–6 weeks

Tolerance & Individual Response

• Water retention in some users
• Tingling or flushing
• Temporary changes in sleep patterns

Gentle range
1 mg weekly | 16–24 weeks

Common range
1.5 – 2 mg weekly | 12–16 weeks

Intensive range (short term)
2.5 – 3 mg weekly | 6–8 weeks

Tolerance & Individual Response

• Injection-site discomfort
• Headache
• Mild fatigue

Gentle range
0.1 mg daily | 12–20 weeks

Common range
0.2 – 0.3 mg daily | 8–12 weeks

Intensive range (short term)
0.4 – 0.5 mg daily | 4–6 weeks

Tolerance & Individual Response

• Hunger changes
• Lightheadedness in some users
• Temporary flushing

Gentle range
2 – 3 mg daily | 10–20 days

Common range
5 mg daily | 10–20 days

Intensive range (short term)
5 – 10 mg daily | 10–14 days

How This Is Commonly Used in Practice

Typically explored in short cycles rather than continuous use, often repeated after several months.

Tolerance & Individual Response

Some individuals may notice mild, temporary effects, while many experience no noticeable issues.

• Temporary fatigue
• Lightheadedness
• Mild headache
• Changes in sleep patterns

Gentle range
2 – 3 mg 2× weekly | 8–12 weeks

Common range
4 – 6 mg 2× weekly | 6–10 weeks

Intensive range (short term)
8 – 12 mg weekly | 3–6 weeks

How This Is Commonly Used in Practice
Usually explored in short-to-medium blocks, often alongside metabolic support.

Tolerance & Individual Response

• Transient fatigue in some users
• Headache
• Appetite changes

Gentle range
100 – 200 mg 2–3× weekly | 12–24 weeks

Common range
300 – 600 mg 2× weekly | 8–16 weeks

Intensive range (short term)
600 – 1,000 mg weekly | 4–8 weeks

How This Is Commonly Used in Practice
Most users favour moderate, consistent exposure rather than high-dose loading, particularly for longer-term antioxidant support.

Tolerance & Individual Response

• Warmth or flushing
• Mild nausea
• Headache
• Injection-site irritation in some users

(Subcutaneous)

Gentle range
0.2 – 0.3 mg daily | 6–10 weeks

Common range
0.4 – 0.6 mg daily | 4–8 weeks

Intensive range (short term)
0.7 – 1.0 mg daily | 3–6 weeks

How This Is Commonly Used in Practice
Often explored in short-to-medium cycles for cognitive support and mental performance.

Tolerance & Individual Response

• Headache in some users
• Mild agitation
• Sleep disruption
• Temporary anxiety

(Subcutaneous)

Gentle range
0.2 – 0.3 mg daily | 8–12 weeks

Common range
0.4 – 0.6 mg daily | 6–10 weeks

Intensive range (short term)
0.7 – 1.0 mg daily | 3–6 weeks

How This Is Commonly Used in Practice

Used in moderate daily amounts over several weeks, often for emotional balance and stress resilience.

Tolerance & Individual Response

• Mild sedation in some users
• Headache
• Temporary mood changes
• Injection-site irritation

Gentle range
0.1 – 0.2 mg daily | 6–10 weeks

Common range
0.2 – 0.4 mg daily | 4–8 weeks

Intensive range (short term)
0.5 – 0.8 mg daily | 2–4 weeks

How This Is Commonly Used in Practice
Most commonly used in short cycles focused on sleep and recovery quality.

Tolerance & Individual Response

• Drowsiness
• Vivid dreams
• Morning grogginess
• Headache in some users

Gentle range
0.5 – 0.75 mg as-needed

Common range
1.0 – 1.5 mg as-needed

Intensive range (short term)
1.75 – 2.0 mg limited use

Tolerance & Individual Response

• Nausea in some users
• Facial flushing
• Headache
• Increased blood pressure in sensitive individuals

Context Note

PT-141 is primarily studied and used in intermittent, event-based models rather than continuous weekly schedules. Fixed long-term weekly dosing is uncommon.

(BPC-157 10 mg + TB-500 10 mg)

20 mg total blend in 2 mL

Gentle range

0.3–0.5 mg total blend daily

Equivalent to approximately:

• 0.15–0.25 mg BPC-157

• 0.15–0.25 mg TB-500

Approx. 3–5 IU daily

Common range

0.6–1.0 mg total blend daily

Equivalent to approximately:

• 0.3–0.5 mg BPC-157

• 0.3–0.5 mg TB-500

Approx. 6–10 IU daily

Intensive range (short term)

1.0–1.5 mg total blend daily

Equivalent to approximately:

• 0.5–0.75 mg BPC-157

• 0.5–0.75 mg TB-500

Approx. 10–15 IU daily

How This Is Commonly Used in Practice

Often explored in recovery-focused protocols targeting connective tissue, joints, muscles, and systemic repair pathways.

Tolerance & Individual Response

• Mild injection-site irritation in some users

• Temporary fatigue in sensitive individuals

• Occasional headaches during higher-range use

(BPC-157 10 mg + TB-500 10 mg + KPV 10 mg)

30 mg total blend in 2 mL

Gentle range

0.3–0.6 mg total blend daily

Equivalent to approximately:

• 0.1–0.2 mg BPC-157

• 0.1–0.2 mg TB-500

• 0.1–0.2 mg KPV

Approx. 2–4 IU daily

Common range

0.6–1.2 mg total blend daily

Equivalent to approximately:

• 0.2–0.4 mg BPC-157

• 0.2–0.4 mg TB-500

• 0.2–0.4 mg KPV

Approx. 4–8 IU daily

Intensive range (short term)

1.2–1.8 mg total blend daily

Equivalent to approximately:

• 0.4–0.6 mg BPC-157

• 0.4–0.6 mg TB-500

• 0.4–0.6 mg KPV

Approx. 8–12 IU daily

How This Is Commonly Used in Practice

Commonly explored where recovery, inflammation modulation, gut support, and tissue repair are all desired simultaneously.

Tolerance & Individual Response

• Mild digestive shifts in sensitive individuals

• Injection-site irritation possible

• Occasional fatigue or headache at higher ranges

(GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg)

80 mg total blend in 2 mL

Gentle range

0.8–1.6 mg total blend daily

Equivalent to approximately:

• 0.5–1.0 mg GHK-Cu

• 0.1–0.2 mg BPC-157

• 0.1–0.2 mg TB-500

• 0.1–0.2 mg KPV

Approx. 2–4 IU daily

Common range

1.6–3.2 mg total blend daily

Equivalent to approximately:

• 1.0–2.0 mg GHK-Cu

• 0.2–0.4 mg BPC-157

• 0.2–0.4 mg TB-500

• 0.2–0.4 mg KPV

Approx. 4–8 IU daily

Intensive range (short term)

3.2–4.8 mg total blend daily

Equivalent to approximately:

• 2.0–3.0 mg GHK-Cu

• 0.4–0.6 mg BPC-157

• 0.4–0.6 mg TB-500

• 0.4–0.6 mg KPV

Approx. 8–12 IU daily

How This Is Commonly Used in Practice

Often explored in protocols focused on skin quality, connective tissue support, recovery, inflammation modulation, and regenerative aesthetic pathways.

Tolerance & Individual Response

• Temporary skin sensitivity in some individuals

• Mild injection-site irritation possible

• Occasional fatigue or headaches during adaptation

(CJC-1295 no DAC 10 mg + Ipamorelin 10 mg)

20 mg total blend in 3 mL

Gentle range

130–200 mcg total blend nightly

Equivalent to approximately:

• 65–100 mcg CJC-1295 no DAC

• 65–100 mcg Ipamorelin

Approx. 2–3 IU nightly

Common range

200–330 mcg total blend nightly

Equivalent to approximately:

• 100–165 mcg CJC-1295 no DAC

• 100–165 mcg Ipamorelin

Approx. 3–5 IU nightly

Intensive range (short term)

330–500 mcg total blend nightly

Equivalent to approximately:

• 165–250 mcg CJC-1295 no DAC

• 165–250 mcg Ipamorelin

Approx. 5–7.5 IU nightly

How This Is Commonly Used in Practice

Often explored in recovery, sleep, body composition, and performance-oriented protocols supporting endogenous growth hormone signalling.

Tolerance & Individual Response

• Mild water retention possible

• Temporary hunger increase in some users

• Vivid dreams or transient lethargy may occur

KPV

20 mg in 2 mL

Gentle range

0.25–0.5 mg daily

Approx. 2.5–5 IU daily

Common range

0.5–1.0 mg daily

Approx. 5–10 IU daily

Intensive range (short term)

1.0–1.5 mg daily

Approx. 10–15 IU daily

How This Is Commonly Used in Practice

Often explored for gut support, inflammation modulation, recovery, and systemic resilience protocols.

Tolerance & Individual Response

• Mild digestive changes in sensitive individuals

• Occasional fatigue or light nausea

• Some users report rapid changes in inflammatory symptoms

10 mg in 2 mL

Gentle range

0.1–0.2 mg daily

Approx. 2–4 IU daily

Common range

0.2–0.5 mg daily

Approx. 4–10 IU daily

Intensive range (short term)

0.5–1.0 mg daily

Approx. 10–20 IU daily

How This Is Commonly Used in Practice

Often explored in protocols related to hormonal signalling, reproductive health pathways, libido, and endocrine support.

Tolerance & Individual Response

• Temporary flushing or warmth in some users

• Occasional headaches or nausea

• Sensitivity may vary considerably between individuals

20 mg in 2 mL

Gentle range

0.1–0.2 mg nightly

Approx. 1–2 IU nightly

Common range

0.2–0.4 mg nightly

Approx. 2–4 IU nightly

Intensive range (short term)

0.4–0.6 mg nightly

Approx. 4–6 IU nightly

How This Is Commonly Used in Practice

Typically used in evening protocols designed to support natural growth hormone signalling and recovery processes.

Tolerance & Individual Response

• Mild water retention in some individuals

• Temporary fatigue or vivid dreams

• Injection-site irritation possible

5 mg in 2 mL

Gentle range

0.1–0.2 mg daily

Approx. 4–8 IU daily

Common range

0.2–0.5 mg daily

Approx. 8–20 IU daily

Intensive range (short term)

0.5–1.0 mg daily

Approx. 20–40 IU daily

How This Is Commonly Used in Practice

Frequently explored in short-duration protocols focused on immune modulation, antimicrobial research, and systemic resilience.

Tolerance & Individual Response

• Injection-site irritation can occur

• Some users report fatigue or flu-like sensations

• Higher ranges are generally kept shorter-term

20 mg in 2 mL

Gentle range

0.25–0.5 mg daily

Approx. 2.5–5 IU daily

Common range

0.5–1.5 mg daily

Approx. 5–15 IU daily

Intensive range (short term)

1.5–3.0 mg daily

Approx. 15–30 IU daily

How This Is Commonly Used in Practice

Often explored in immune-support and resilience-focused protocols, particularly during periods of physiological stress.

Tolerance & Individual Response

• Mild fatigue or lethargy in some individuals

• Injection-site irritation possible

• Temporary flu-like sensations may occur during adaptation

Disclaimer

All products available through Nugenyx are supplied strictly for laboratory research and scientific investigation purposes only.

They are not intended for human or veterinary use, nor for the diagnosis, treatment, cure, or prevention of any disease.

While we recognise the growing interest in peptides and related compounds, any information shared on this site is provided for educational and informational purposes only and should not be interpreted as medical, therapeutic, or clinical advice.

Statements regarding compounds, mechanisms, or biological pathways are based on published research and are not intended to imply outcomes or applications outside of controlled research settings.

By purchasing from Nugenyx, the buyer acknowledges and agrees that all products will be used solely for research purposes by qualified individuals and in compliance with all applicable laws and regulations.

The buyer further confirms that they are aware of, and responsible for, the legal status, importation rules, and regulatory requirements governing peptides and research compounds within their country or jurisdiction.